Autres langues Agios Pharmaceuticals, Inc.

Actions

AGIO

US00847X1046

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 08/10/2026			Varia. 5j.	Varia. 1 janv.
31,92 ^USD	+0,41%		-1,72%	+17,27%

21/09	Agios Pharmaceuticals, Inc. : BofA Securities maintient sa recommandation à l'achat	ZM
30/07	Transcript : Agios Pharmaceuticals, Inc., Q2 2026 Earnings Call, Jul 30, 2026

Autres langues

08/10	Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
30/07	Agios Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
30/07	Agios Pharmaceuticals Q2 Loss Narrows as Revenue Increases
30/07	Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q2 Revenue $44.7M, vs. FactSet Est of $26.4M
30/07	Earnings Flash (AGIO) Agios Pharmaceuticals Posts Q2 Net Loss $1.69 a Share, vs. FactSet Est of $1.71 Loss
30/07	Agios Pharmaceuticals: Q2 Earnings Snapshot
30/07	Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
21/07	Agios Pharmaceuticals Inc Announces Topline Results from Phase 2 Trial of Tebapivat in Sickle Cell Disease
21/07	Agios Halts Sickle Cell Treatment Development After Phase 2 Results Fail to Show Differentiation
21/07	Top Premarket Decliners
21/07	Agios scraps sickle cell treatment after trial shows limited benefit
21/07	Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
07/07	Agios Pharmaceuticals Shares Rise After FDA Grants Priority Review for Sickle Cell Treatment
07/07	Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says
07/07	Agios Pharmaceuticals Shares Rise After FDA Grants Priority Review for Sickle Cell Disease Treatment
07/07	Agios Pharmaceuticals, Inc. Receives FDA Priority Review For sNDA For Mitapivat In Sickle Cell Disease
07/07	Agios Says US FDA Grants Priority Review for Mitapivat to Treat Sickle Cell Disease
07/07	U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
29/06	Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell 2000 Defensive Index
29/06	Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) added to Russell Small Cap Comp Growth Benchmark
29/06	Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) added to Russell 2500 Growth Benchmark
29/06	Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
29/06	Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) added to Russell 2000 Growth Benchmark
29/06	Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) added to Russell 3000E Growth Benchmark
29/06	Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) added to Russell 3000 Growth Benchmark